Sonoma Pharmaceuticals (SNOA) Competitors

Sonoma Pharmaceuticals logo
$0.72 -0.09 (-10.83%)
Closing price 04:00 PM Eastern
Extended Trading
$0.72 -0.01 (-0.69%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SNOA vs. TAOX, CRVO, TXMD, COCP, and AYTU

Should you buy Sonoma Pharmaceuticals stock or one of its competitors? Sonoma Pharmaceuticals's main competitors and comparable companies include Synaptogenix (TAOX), CervoMed (CRVO), TherapeuticsMD (TXMD), Cocrystal Pharma (COCP), and Aytu BioPharma (AYTU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Sonoma Pharmaceuticals compare to Synaptogenix?

Sonoma Pharmaceuticals (NASDAQ:SNOA) and Synaptogenix (NASDAQ:TAOX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

Sonoma Pharmaceuticals has higher revenue and earnings than Synaptogenix. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sonoma Pharmaceuticals$19.53M0.21-$3.17M-$0.91N/A
Synaptogenix$300K46.36-$28.74M-$3.85N/A

2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 1.0% of Sonoma Pharmaceuticals shares are held by insiders. Comparatively, 2.7% of Synaptogenix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Sonoma Pharmaceuticals has a net margin of -7.65% compared to Synaptogenix's net margin of -768.22%. Sonoma Pharmaceuticals' return on equity of -4.82% beat Synaptogenix's return on equity.

Company Net Margins Return on Equity Return on Assets
Sonoma Pharmaceuticals-7.65% -4.82% -1.52%
Synaptogenix -768.22%-68.89%-49.33%

In the previous week, Synaptogenix had 1 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 1 mentions for Synaptogenix and 0 mentions for Sonoma Pharmaceuticals. Sonoma Pharmaceuticals' average media sentiment score of 0.00 beat Synaptogenix's score of -1.29 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Sonoma Pharmaceuticals Neutral
Synaptogenix Negative

Sonoma Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sonoma Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Synaptogenix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Sonoma Pharmaceuticals beats Synaptogenix on 7 of the 13 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to CervoMed?

Sonoma Pharmaceuticals (NASDAQ:SNOA) and CervoMed (NASDAQ:CRVO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Sonoma Pharmaceuticals has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market. Comparatively, CervoMed has a beta of -0.62, indicating that its share price is 162% less volatile than the broader market.

2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. Comparatively, 25.2% of CervoMed shares are owned by institutional investors. 1.0% of Sonoma Pharmaceuticals shares are owned by company insiders. Comparatively, 35.8% of CervoMed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CervoMed has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -7.65%. Sonoma Pharmaceuticals' return on equity of -4.82% beat CervoMed's return on equity.

Company Net Margins Return on Equity Return on Assets
Sonoma Pharmaceuticals-7.65% -4.82% -1.52%
CervoMed N/A -164.95%-133.71%

CervoMed has a consensus target price of $21.00, indicating a potential upside of 1,478.95%. Given CervoMed's stronger consensus rating and higher possible upside, analysts clearly believe CervoMed is more favorable than Sonoma Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sonoma Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
CervoMed
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71

In the previous week, CervoMed had 3 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 3 mentions for CervoMed and 0 mentions for Sonoma Pharmaceuticals. CervoMed's average media sentiment score of 0.44 beat Sonoma Pharmaceuticals' score of 0.00 indicating that CervoMed is being referred to more favorably in the news media.

Company Overall Sentiment
Sonoma Pharmaceuticals Neutral
CervoMed Neutral

Sonoma Pharmaceuticals has higher revenue and earnings than CervoMed. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sonoma Pharmaceuticals$19.53M0.21-$3.17M-$0.91N/A
CervoMed$4.01M5.02-$26.97M-$2.77N/A

Summary

CervoMed beats Sonoma Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to TherapeuticsMD?

TherapeuticsMD (NASDAQ:TXMD) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by insiders. Comparatively, 1.0% of Sonoma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

TherapeuticsMD has a net margin of 3.26% compared to Sonoma Pharmaceuticals' net margin of -7.65%. TherapeuticsMD's return on equity of 0.57% beat Sonoma Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
TherapeuticsMD3.26% 0.57% 0.41%
Sonoma Pharmaceuticals -7.65%-4.82%-1.52%

In the previous week, TherapeuticsMD had 2 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 2 mentions for TherapeuticsMD and 0 mentions for Sonoma Pharmaceuticals. TherapeuticsMD's average media sentiment score of 1.50 beat Sonoma Pharmaceuticals' score of 0.00 indicating that TherapeuticsMD is being referred to more favorably in the media.

Company Overall Sentiment
TherapeuticsMD Very Positive
Sonoma Pharmaceuticals Neutral

TherapeuticsMD has higher earnings, but lower revenue than Sonoma Pharmaceuticals. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TherapeuticsMD$3.02M6.93-$570K$0.0630.17
Sonoma Pharmaceuticals$19.53M0.21-$3.17M-$0.91N/A

TherapeuticsMD has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TherapeuticsMD
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Sonoma Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

TherapeuticsMD beats Sonoma Pharmaceuticals on 11 of the 13 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to Cocrystal Pharma?

Sonoma Pharmaceuticals (NASDAQ:SNOA) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

Sonoma Pharmaceuticals has higher revenue and earnings than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sonoma Pharmaceuticals$19.53M0.21-$3.17M-$0.91N/A
Cocrystal PharmaN/AN/A-$8.83M-$0.77N/A

Sonoma Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sonoma Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Cocrystal Pharma
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are owned by institutional investors. 1.0% of Sonoma Pharmaceuticals shares are owned by company insiders. Comparatively, 39.4% of Cocrystal Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cocrystal Pharma has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -7.65%. Sonoma Pharmaceuticals' return on equity of -4.82% beat Cocrystal Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Sonoma Pharmaceuticals-7.65% -4.82% -1.52%
Cocrystal Pharma N/A -320.01%-158.73%

In the previous week, Cocrystal Pharma had 13 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 13 mentions for Cocrystal Pharma and 0 mentions for Sonoma Pharmaceuticals. Cocrystal Pharma's average media sentiment score of 0.27 beat Sonoma Pharmaceuticals' score of 0.00 indicating that Cocrystal Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
Sonoma Pharmaceuticals Neutral
Cocrystal Pharma Neutral

Summary

Cocrystal Pharma beats Sonoma Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to Aytu BioPharma?

Aytu BioPharma (NASDAQ:AYTU) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Aytu BioPharma has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

Aytu BioPharma presently has a consensus target price of $8.60, suggesting a potential upside of 223.31%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, research analysts plainly believe Aytu BioPharma is more favorable than Sonoma Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aytu BioPharma
2 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00
Sonoma Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Sonoma Pharmaceuticals has lower revenue, but higher earnings than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aytu BioPharma$57.57M0.50-$14.25M-$1.78N/A
Sonoma Pharmaceuticals$19.53M0.21-$3.17M-$0.91N/A

33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 6.1% of Aytu BioPharma shares are owned by company insiders. Comparatively, 1.0% of Sonoma Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Aytu BioPharma had 25 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 25 mentions for Aytu BioPharma and 0 mentions for Sonoma Pharmaceuticals. Aytu BioPharma's average media sentiment score of 0.06 beat Sonoma Pharmaceuticals' score of 0.00 indicating that Aytu BioPharma is being referred to more favorably in the media.

Company Overall Sentiment
Aytu BioPharma Neutral
Sonoma Pharmaceuticals Neutral

Sonoma Pharmaceuticals has a net margin of -7.65% compared to Aytu BioPharma's net margin of -34.34%. Sonoma Pharmaceuticals' return on equity of -4.82% beat Aytu BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Aytu BioPharma-34.34% -72.58% -19.26%
Sonoma Pharmaceuticals -7.65%-4.82%-1.52%

Summary

Aytu BioPharma beats Sonoma Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Sonoma Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SNOA vs. The Competition

MetricSonoma PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.65M$13.02B$7.41B$10.84B
Dividend YieldN/A2.60%2.48%4.74%
P/E Ratio-0.7927.3232.4728.82
Price / Sales0.196.528.065.37
Price / CashN/A15.5320.7221.66
Price / Book0.555.164.303.50
Net Income-$3.17M$2.86B$3.50B$394.12M
7 Day Performance-33.76%-7.23%-7.93%-8.92%
1 Month Performance-37.22%-9.61%-10.46%-12.02%
1 Year Performance-77.85%-8.11%-2.79%-9.62%

Sonoma Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SNOA
Sonoma Pharmaceuticals
0.5817 of 5 stars
$0.72
-10.8%
N/A-75.8%$3.65M$19.53MN/A260
TAOX
Synaptogenix
0.3844 of 5 stars
$2.54
-1.6%
N/A-73.4%$20.76M$300KN/A4
CRVO
CervoMed
3.0007 of 5 stars
$1.77
+29.2%
$21.00
+1,086.4%
-84.6%$20.73M$4.01MN/A15
TXMD
TherapeuticsMD
0.9397 of 5 stars
$1.85
+6.3%
N/A+9.7%$20.14M$3.02M92.501
COCP
Cocrystal Pharma
0.9654 of 5 stars
$1.02
-1.0%
N/A-2.0%$19.84MN/AN/A10

Related Companies and Tools


This page (NASDAQ:SNOA) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners